


	1999	2000	2001	2002	2003	Sept. 2004
<p>VIOXX Approval May 1999</p> 						
VIGOR	Jan 1999 Trial initiated	March 2000: Preliminary Results received, submitted to FDA and publicized June: Final results and draft prescribing info to FDA		April 2002 US prescribing information updated		
APPROVe	Oct 1999 Protocol finalized	Feb 2000 Enrollment begins	Nov 2001 Enrollment completed			Sept 2004 Trial terminated Merck voluntarily withdraws VIOXX
Alzheimer's	Alzheimer's prevention trial already underway Feb 1999 Alzheimer's treatment trial begins			June 2002 Pooled Alzheimer's analysis presented	June 2003 Updated Pooled Alzheimer's analysis presented	
VICTOR			Sept 2001 Letter of intent with Oxford University	April 2002 First Patient enrolled		Sept 2004 Trial terminated
ViP					Mar 2003 Protocol finalized June 2003 Enrollment begins	Sept 2004 Trial terminated

Forward-Looking Statement

This document contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Merck's business, particularly those mentioned in the cautionary statements in Item 1 of Merck's Form 10-K for the year ended Dec. 31, 2003, and in its periodic reports on Form 10-Q and Form 8-K (if any) which the company incorporates by reference.